Q4 2024 Neuroone Medical Technologies Corp Earnings Call Transcript
Key Points
- NeuroOne Medical Technologies Corp (NMTC) successfully achieved 510(k) clearance from the FDA for their OneRF Ablation System, marking it as the first and only FDA-cleared system for both electrical activity reporting and nervous tissue ablation.
- The company secured a strategic partnership with Zimmer Biomet, providing a broad distribution network in the US and certain international geographies.
- NeuroOne received a $3 million upfront license payment from Zimmer Biomet, with potential for additional milestone payments, strengthening their financial position.
- The company projects significant revenue growth for fiscal year 2025, with expected revenue between $8 million and $10 million, representing a 132% to 190% increase over 2024.
- NeuroOne is expanding its product applications, targeting additional indications such as RF ablation for facial pain and potentially lower back and knee pain, which could contribute to future revenue growth.
- Product revenue in the fourth quarter of fiscal 2024 decreased to $0.3 million from $0.7 million in the prior year due to the cancellation of a Zimmer Biomet purchase order.
- The company reported a net loss of $3.3 million for the fourth quarter of fiscal 2024, slightly higher than the $3.1 million net loss in the same period of the prior year.
- Cash and cash equivalents decreased significantly to $1.5 million as of September 30, 2024, from $5.3 million the previous year, indicating potential liquidity concerns.
- Working capital also decreased to $2.4 million as of September 30, 2024, compared to $5.5 million the previous year, which may impact operational flexibility.
- Despite the progress, the company remains non-compliant with Nasdaq's minimum bid price requirement, which could pose a risk to its stock listing.
Good day, ladies and gentlemen, welcome to the NeuroOne fourth quarter and fiscal year end 2024 earnings call.
Today's call will be conducted by the company's Chief Executive Officer, Dave Rosa; and Ron McClurg, the company's Chief Financial Officer; Chris Volker, the company's Chief Operating Officer will also be in attendance.
Before I turn the call over to Mr. Rosa. I'd like to remind you that this conference call will include forward-looking statements within the meaning of US federal securities laws with respect to future operations, financial results, events, trends, and performance which are based on management's beliefs and assumptions as of today's call or other specified date. Forward-looking statements may involve known and unknown risks, uncertainties, and other factors which may cause actual results to differ materially from those expressed or implied by such statements. See NeuroOne's financial results press release and SEC filings for information regarding specific risks and uncertainties that could cause actual results to differ. Except as required by laws, NeuroOne
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
